Description: EXACT Therapeutics AS, a clinical stage biotech company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology, infectious diseases, and neurological conditions. The company's ACT platform is under Phase I multi-center international clinical trial in patients with liver metastases secondary to colorectal/pancreatic cancer. EXACT Therapeutics AS has a collaboration with GE Healthcare to develop an ultrasound probe to be used in studies using acoustic cluster therapy across various disease conditions. The company was formerly known as Phoenix Solutions AS. EXACT Therapeutics AS was incorporated in 2012 and is based in Oslo, Norway.
Home Page: www.exact-tx.com
Østre Aker vei 19
Oslo,
0581
Norway
Phone:
Officers
| Name | Title |
|---|---|
| Dr. Per Walday Ph.D. | Chief Exec. Officer |
| Dr. Masha Paule Nathalie Legris Stromme DPHIL | Vice-Chair of the Board |
| Dr. Andrew John Healey | Co Founder & Chief Scientific Officer |
| Dr. Svein Kvåle | Co Founder & COO |
| Dr. Per Christian Sontum | Founder |
| Mr. Dominic Michael Moreland Aca | Chief Financial Officer |
| Mr. John M. Edminson | Chief Financial Officer |
| Mr. Ragnar Bendicksen | VP of Technology |
| Dr. Hilary McElwaine-Johnn M.D. | Chief Medical Officer |
| Dr. Amir Snapir M.D., Ph.D. | Chief Medical Officer |
Exchange: OL
Country: NO
Currency: Norwegian Krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.5499 |
| Price-to-Sales TTM: | 8802.906 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 8 |